An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
NCT01751867
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
135
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
Decitabine at 15 mg/m2
DRUG:
Decitabine at 20 mg/m2
Sponsor
Xian-Janssen Pharmaceutical Ltd.